President Trump plans to eliminate federal subsidies that help millions of Medicare beneficiaries afford prescription drug premiums, according to reporting from the New York Times. The move would affect seniors currently receiving financial assistance under the Enhanced Extra Help program and related subsidy mechanisms that reduce out-of-pocket drug costs.
Medicare beneficiaries earning up to 150 percent of the federal poverty line currently qualify for these subsidies, which can cover substantial portions of their monthly premiums. Removing this support would force older adults to absorb the full cost of their prescription drug coverage or risk going without medications entirely.
The proposal comes as drug costs remain a persistent burden for American seniors. In 2024, research from the Kaiser Family Foundation documented that approximately 4 million Medicare beneficiaries received Enhanced Extra Help subsidies. Many of these individuals live on fixed incomes and already struggle to afford healthcare expenses beyond prescription drugs.
Healthcare advocates and senior organizations have raised concerns about the implications. Reducing premium assistance could lead some beneficiaries to skip doses, split pills, or delay refills to stretch their medications further, all documented harms from medication cost barriers. The American Association of Retired Persons and other advocacy groups typically oppose cuts to prescription drug support programs.
Policy experts note that removing these subsidies would shift costs directly to vulnerable populations with limited financial flexibility. Seniors on Medicare often face choices between purchasing medications and paying for housing, food, or utilities.
The proposed changes would require congressional approval and implementation through the Department of Health and Human Services. Exact timing and phase-in periods remain unclear, though the administration has indicated changes could take effect in 2025.
Prescription drug affordability has remained a bipartisan concern, particularly after Congress passed the Inflation Reduction Act in 2022, which included drug price negotiation provisions. How Congress responds to this proposed subsidy elimination will shape what millions of older Americans ultimately pay for their medications.